A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b

A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b

Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) have become a critical regimen for tumor therapy, but the efficacy of monotherapy is usually limited by drug resistance and multiple angiogenic mechanisms. Complement proteins are becoming potential candidates for cancer-targ...

Full description

Bibliographic Details
Main Authors: Huiling Wang, Yiming Li, Gang Shi, Yuan Wang, Yi Lin, Qin Wang, Yujing Zhang, Qianmei Yang, Lei Dai, Lin Cheng, Xiaolan Su, Yang Yang, Shuang Zhang, Zhi Li, Jia Li, Yuquan Wei, Dechao Yu, Hongxin Deng
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:Molecular Therapy: Oncolytics
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770519301056

Internet

http://www.sciencedirect.com/science/article/pii/S2372770519301056

Similar Items